DBV Technologies (NASDAQ:DBVT) Price Target Cut to $47.00 by Analysts at Citizens Jmp

DBV Technologies (NASDAQ:DBVT) had its target price reduced by equities research analysts at Citizens Jmp from $55.00 to $47.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp‘s target price would suggest a potential upside of 354.11% from the company’s current price.

Other equities analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a research note on Thursday, October 15th. Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Citigroup restated a “market outperform” rating on shares of DBV Technologies in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $46.50.

DBV Technologies Price Performance

Shares of DBVT traded down $0.30 on Thursday, hitting $10.35. The company’s stock had a trading volume of 616,049 shares, compared to its average volume of 317,838. The company has a market capitalization of $650.81 million, a PE ratio of -2.96 and a beta of -1.04. DBV Technologies has a fifty-two week low of $8.63 and a fifty-two week high of $26.18. The company has a 50 day moving average price of $11.71 and a 200 day moving average price of $17.00.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Wednesday, October 28th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.41). DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%. The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.58 million. On average, equities analysts forecast that DBV Technologies will post -2.05 EPS for the current year.

Institutional Trading of DBV Technologies

Hedge funds have recently modified their holdings of the stock. Vivo Capital LLC grew its stake in shares of DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after purchasing an additional 205,943 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of DBV Technologies in the first quarter valued at approximately $21,159,000. Perceptive Advisors LLC bought a new position in DBV Technologies in the 1st quarter worth approximately $20,146,000. Atika Capital Management LLC raised its position in DBV Technologies by 31.1% in the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company’s stock worth $5,667,000 after purchasing an additional 64,419 shares during the last quarter. Finally, Elmind Capital LP bought a new position in DBV Technologies in the 1st quarter worth approximately $5,536,000. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.